Alterations in lung macrophage antimicrobial activity associated with viral pneumonia.
Secondary bacterial infections are a common sequelae of viral pneumonias. To study 2 functions of the phagocytic defenses of the lung, macrophages were obtained by lung lavage from parainfluenza 1 virus-infected and noninfected mice. The phagocytic capacities (binding, ingestion, and killing) of these cells were assessed in vitro against viable Candida krusei. Viral pneumonia resulted in a progressive suppression (through day 7 of the infection) of the ability of macrophages to bind candida to their surfaces by nonimmunological or complement receptors; ingestion and intracellular killing of candida were also decreased. After day 7, all these functions returned and, in fact, cells with enhanced activities were present on day 17. After introduction of virus into the lungs, the lung macrophage population increased significantly between days 3 and 7 of infection. This resulted in an increase in the phagocytic potential of the lung, despite the virus-associated suppression of the phagocytic activity in a portion of the macrophages. However, the ability of the macrophages to kill ingested microorganisms was also reduced, resulting in an overall deficiency in the lung macrophage defenses. It was concluded that viral pneumonia was associated with at least two suppressive effects on the lung macrophage-decreased receptor activity and microbicidal activity-resulting in a deficiency in the lung phagocytic defenses represented by these cells. These effects were maximal 1 week after infection and could account for the increased susceptibility of these lungs to secondary bacterial pneumonias. In contrast, during the period of convalescence, the lung macrophage antimicrobial activities were increased and reflected in enhanced resistance of the lungs to infections.
D000818:Animals; D002175:Candida / Q000276:immunology* / Q000378:metabolism; D005260:Female; D066298:In Vitro Techniques; D008168:Lung / Q000166:cytology; D008264:Macrophages / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D010222:Parainfluenza Virus 1, Human; D018184:Paramyxoviridae Infections / Q000276:immunology*; D010587:Phagocytosis; D011024:Pneumonia, Viral / Q000276:immunology*; D011951:Receptors, Complement / Q000378:metabolism
D011951:Receptors, Complement